Jump to content

Thomas Martin (pathologist)

From Wikipedia, the free encyclopedia

Thomas John Martin
Born
Thomas John "Jack" Martin

(1937-01-24) January 24, 1937 (age 87)
EducationUniversity of Melbourne[1][3]
Degrees:
  • Bachelor of Medicine (MB) (1960)[1]
  • Bachelor of Surgery (BS) (1960)[1]
  • Doctor of Medicine (MD) (1969)[1]
  • Doctor of Science (DSc) (1979)[1]
Alma materUniversity of Melbourne
Known forDiscovery of parathyroid hormone-related protein (PTHrP)
Scientific career
Fields
Institutions

Thomas John "Jack" Martin is an Australian pathologist, emeritus professor of medicine, physician and academic at University of Melbourne,[1][3] and researcher who, in 1987, by leading a former team of researchers at the same university, discovered a proteinaceous hormone called parathyroid hormone-related protein (PTHrP).[4][5] In September 2005, further research was conducted by the team of Dengshun Miao[6] and David Goltzman at the Calcium Research Laboratory and Department of Medicine, Royal Victoria Hospital of the McGill University Health Centre, and others.[6]

Martin is a member of Natalie A. Sims' laboratory[7] at Saint Vincent's Institute of Medical Research.[8] He works in the institute's Division of Medicine, Dentistry and Health Sciences, and his primary interest is cell biology of bones.[9]

Research career

[edit]

Martin was the director of St Vincent's Institute from 1988 to 2002.[10] In September 2005, Martin found that PTHrP produced by osteoblasts is a physiological regulator of bone formation.[11]

In July 2022, Martin and his team at Natalie A. Sims' lab, after much research on mice, found that deletion of the gene that codes for a receptor protein called granulocyte colony-stimulating factor receptor (G-CSF) increases physiological dysfunction of cortical bones of mice having hyperactivated STAT3 proteins in their bone cells.[12] Cortical bone maturation depends on SOCS3-mediated suppression of interleukin-6 cytokine-induced STAT3 phosphorylation in bone cells, which form the cellular network embedded in bone matrix. They concluded that G-CSFR signaling could indirectly limit bone resorption and angiogenesis, and thereby has a major role in replacing condensed trabecular bone with lamellar bone during cortical bone formation.[12]

Awards and honours

[edit]
Year Award
1969 Fellow of the Royal Australasian College of Physicians (FRACP)[1]
1971 Selwyn Smith Prize for medical research[1]
1974 Eric Susman Prize received from the Royal Australasian College of Physicians[1]
1990 Lemberg Medal received from the Australian Biochemical Society[1]
1992
  • Honorary Doctor of Medicine (MD(Hon)) received from the University of Sheffield[1]
  • Dale Medal received from the British Society for Endocrinology[1]
  • In August 2022, an award "TJ Martin Medal" was named in Martin's honour.[10] The medal was awarded to gastroenterologist Chamara Basnayake at St Vincent's Hospital for his research into the multidisciplinary treatment of functional gastrointestinal disorders.[10]

References

[edit]
  1. ^ a b c d e f g h i j k l m n o p q r s Centre for Transformative Innovation, Swinburne University of Technology. "Martin, Thomas John (Jack)". Encyclopedia of Australian Science and Innovation. Archived from the original on January 1, 2023. Retrieved October 30, 2022.
  2. ^ "Prof T.J. (Jack) Martin". Saint Vincent's Institute. Archived from the original on October 30, 2022. Retrieved October 30, 2022.
  3. ^ a b Fioritti, Nathan (November 22, 2016). "Professor Emeritus Thomas John Martin AO". Faculty of Medicine, Dentistry and Health Sciences. Archived from the original on October 29, 2022. Retrieved October 30, 2022.
  4. ^ Martin TJ, Moseley JM, Gillespie MT (1991). "Parathyroid hormone-related protein: biochemistry and molecular biology". Critical Reviews in Biochemistry and Molecular Biology. 26 (3–4): 377–395. doi:10.3109/10409239109114073. PMID 1935171. Archived from the original on October 17, 2022. Retrieved October 29, 2022.
  5. ^ US patent 5460978A, Martin TJ, Moseley JM, Kemp BE, Wettenhall RE, "Protein active in humoral hypercalcemia of malignancy-PthrP", issued October 24, 1995, assigned to University of Melbourne 
  6. ^ a b Miao, D.; He, B.; Jiang, Y.; Kobayashi, T.; Sorocéanu, M. A.; Zhao, J.; et al. (September 2005). "Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34". The Journal of Clinical Investigation. 115 (9): 2402–2411. doi:10.1172/JCI24918. PMC 1193882. PMID 16138191.
  7. ^ Sims, Natalie A. "Natalie A Sims's Lab". ResearchGate.
  8. ^ Martin, Thomas J. "Thomas Martin - Saint Vincent's Institute". ResearchGate. Archived from the original on August 11, 2022. Retrieved October 29, 2022.
  9. ^ "Prof Thomas Martin". Find an Expert - University of Melbourne. Archived from the original on November 4, 2022. Retrieved October 29, 2022.
  10. ^ a b c "2022 TJ Martin Medal Award Winner". ACMD. Archived from the original on October 30, 2022. Retrieved October 30, 2022.
  11. ^ Martin TJ (September 2005). "Osteoblast-derived PTHrP is a physiological regulator of bone formation". The Journal of Clinical Investigation. 115 (9): 2322–2324. doi:10.1172/JCI26239. PMC 1193889. PMID 16138187.
  12. ^ a b Isojima, Tsuyoshi; Walker, Emma C; Poulton, Ingrid J; McGregor, Narelle E; Wicks, Ian P; Gooi, Jonathan H; Martin, T John; Sims, Natalie A (July 20, 2022). "G-CSF Receptor Deletion Amplifies Cortical Bone Dysfunction in Mice With STAT3 Hyperactivation in Osteocytes". Journal of Bone and Mineral Research. 37 (10): 1876–1890. doi:10.1002/jbmr.4654. ISSN 0884-0431.